1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Yantai Zhenghai Biotechnology Co., Ltd.

Yantai Zhenghai Biotechnology Co., Ltd.

300653.SZ
Yantai Zhenghai Biotechnology Co., Ltd.CN flagShenzhen Stock Exchange
14.43
CNY
-0.60
- -
2.56BMarket Cap
Yantai Zhenghai Biotechnology Co., Ltd.
300653.SZ
(Shenzhen Stock Exchange)

Recent

price

14.43

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
1.05
1.12
1.13
1.19
1.55
1.64
2.23
2.99
2.3
2.02
2.03
1.99
Revenue per Share
- -
- -
- -
0.35
0.34
0.38
0.48
0.59
0.66
0.94
1.28
1.06
0.75
0.46
0.54
Basic EPS, GAAP
- -
- -
- -
0.33
0.1
0.34
0.39
0.23
0.09
0.87
0.91
0.82
0.76
0.49
-0.08
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
0.22
0.27
0.33
0.17
0.73
0.6
0.8
0.46
- -
Dividend per Share
- -
- -
- -
0.68
0.93
1.24
1.32
1.58
2.08
2.76
4.25
3.77
3.73
3.74
3.58
Book Value per Share
- -
- -
- -
1.39
1.56
2.88
2.69
3.02
3.38
4.17
5.71
5.07
4.77
4.8
4.63
Tangible Book Value per Share
- -
- -
- -
123
135
161
180
181
179
179
145
180
180
179
178
Basic Weighted Avg Shares
59
77
105
128
151
183
216
280
293
400
433
414
363
364
353
Sales/Revenue/Turnover
22.61
22.71
31.03
30.58
28.32
34.17
39.25
39.12
41.95
43.62
47.36
46.6
36.98
20.76
25.42
Operating Margin (%)
- -
- -
3
3
4
4
5
5
6
18
19
21
23
23
- -
Depreciation Expense
9
16
34
42
45
62
86
107
118
169
185
191
135
82
95
Net Income, GAAP
13.68
15.03
14.5
15.31
15.24
14.33
13.71
13.48
13.3
12.02
12.57
12.56
11.64
6.49
9.63
Effective Tax Rate (%)
14.36
20.38
31.96
33.16
30.19
33.74
39.81
38.38
40.35
42.12
42.8
46.16
37.07
22.63
26.94
Profit Margin (%)
-21
7
41
152
168
426
464
411
382
537
604
681
632
648
607
Working Capital
17
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
-6
29
64
179
228
483
529
588
647
785
865
948
889
889
854
Total Equity
- -
21.56
46.1
27.02
17.55
14.89
14.32
16.86
17.19
21.39
21.59
18.42
12.85
7.91
9.32
Return on Invested Capital (%)
- -
31.55
83.84
66.86
43.64
36.83
38.79
41.02
35.93
38.89
33.42
29.49
19.96
12.29
15.14
Return on Capital (%)
- -
- -
119.47
66.86
43.64
37.96
39.2
41.02
35.93
38.89
33.42
29.49
19.95
12.29
15.14
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
180
180
180
Market Capitalization
3,910
3,990
3,639

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
713
749
684
Cash, Cash Equivalents & STI
622
661
586
Accounts Receivable, Net
48
53
57
Inventories
35
28
30
Total Current Liabilities
81
86
77
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.46%
7%
0.08%
Free Cash Flow
102.68%
173.6%
-35.14%
Net Income, GAAP
10.43%
-2.57%
-38.79%
Sales/Revenue/Turnover
11.97%
5.65%
0.25%
Total Cash Common Dividend
- -
38.87%
-43.25%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
90
108
93
72
363
2025
97
90
88
- -
364
2026
81
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.22
- -
- -
- -
0.75
2025
0.15
- -
- -
- -
0.46
2026
0.08
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.8
2025
- -
- -
- -
- -
0.46
2026
- -
- -
- -
- -
- -
Similar Companies
IR Biosciences Holdings Inc. (IRBS)
SkinBioTherapeutics Plc (SBTX.L)
Imugene Limited (IUGNF)
Endocyte, Inc. (ECYT)
UCB S.A. (UCBJY)
Cynata Therapeutics Limited (CYP.AX)
Business
Yantai Zhenghai Biotechnology Co., Ltd. (300653.SZ) develops, manufactures, and sells magnetic biomaterials and related medical products for orthopedic and dental applications. The company offers a range of bio-orthopedic implants including artificial bone substitutes such as NanoBone, MBCP+, and hydroxyapatite (HA) products; spinal fusion devices like interbody fusion cages and pedicle screws; dental bone graft materials; and wound dressings incorporating silver ions and other bioactive components. These products cater to hospitals, clinics, and dental practices primarily in China, with expanding operations in Asia and select international markets. Founded in 2005 and headquartered in Yantai, Shandong Province, China, the company operates in the biomedical materials segment of the healthcare industry, focusing on tissue engineering and regenerative medicine solutions for bone repair, spinal surgery, and oral implantation. Zhenghai Biotechnology maintains production facilities in Yantai and collaborates with research institutions to advance bioactive ceramics and resorbable implants. It serves as a key supplier to domestic medical device distributors and has no major subsidiaries or parent entities publicly noted. In recent developments, the company announced a strategic partnership in 2024 with a leading European biomaterials firm to co-develop next-generation resorbable spinal implants for Asian markets. Zhenghai completed a RMB 500 million funding round in early 2025 led by domestic healthcare investors to expand manufacturing capacity for its NanoBone product line. Additionally, it launched its ZenGraft dental regeneration system in mid-2025, targeting the growing oral surgery sector, and reorganized its R&D division to prioritize AI-assisted biomaterial design amid competitive pressures in China's medtech landscape.